Business
Annexon is a biopharmaceutical company developing targeted immunotherapies for complement-mediated neuroinflammatory diseases by targeting C1q in the classical complement pathway.
Annexon remained pre-revenue, the net loss widened to $206.7M, and free cash flow fell to -$186.5M.
The read at a glance✓ Audited against SEC data
- Business mix — Complement-targeted immunotherapiesNote
- Revenue — No standard revenue fieldNote
- Profitability — Net loss widened 49.6%Watch
- Cash — Free cash flow was -$186.5MWatch
- Balance sheet — Equity fell 27.8%Watch
- Insiders — 14 buys / 10 sells; cluster buyOK
- Accounting — Forensic screen unavailableNote
Leadership changes
From Annexon, Inc.'s own filings, the day they're filed.
- William Jones · director · appointmenteff. 2025-01-09
Latest filings
- 10-Q · Quarterly report2026-08-12
- 8-K · Company announcement2026-08-12
- 8-K · Company announcement2026-08-10
- 8-K · Company announcement2026-08-06
- 8-K · Company announcement2026-07-30
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Annexon, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.